Glenmark Life Sciences IPO

 

Glenmark Life Sciences is a wholly owned subsidiary of Glenmark Pharmaceuticals Limited.

It is the leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system, pain management and diabetes. They also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

Currently its products are sold in India and exported to Europe, North America, Latin America, Japan, etc. It has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of 31st December 2020

Objects of the Issue:
Glenmark Life Sciences IPO Details

IPO Opening Date	Jul 27, 2021
IPO Closing Date	Jul 29, 2021
Issue Type	Book Built Issue IPO
Face Value	₹2 per equity share
IPO Price	₹695 to ₹720 per equity share
Market Lot	20 Shares
Min Order Quantity	20 Shares
Listing At	BSE, NSE
Issue Size	[.] Eq Shares of ₹2 (aggregating up to ₹1,513.60 Cr)
Fresh Issue	[.] Eq Shares of ₹2 (aggregating up to ₹1,060.00 Cr)
Offer for Sale	6,300,000 Eq Shares of ₹2 (aggregating up to ₹453.60 Cr)

Glenmark Life Sciences IPO Tentative Timetable

IPO Open Date	Jul 27, 2021
IPO Close Date	Jul 29, 2021
Basis of Allotment Date	Aug 3, 2021
Initiation of Refunds	Aug 4, 2021
Credit of Shares to Demat Account	Aug 5, 2021
IPO Listing Date	Aug 6, 2021

• 1) Offer for Sale (OFS) Rs 453.6 Crores: Under OFS selling shareholders would sell the shares and company would not get any proceeds from the issue.

  2) Fresh issue of Rs 1,060 Crores:

  i) To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.

  ii) To finance capital expenditure requirements.

  iii) To meet general corporate purposes.

The Glenmark Life Sciences IPO open date is Jul 27, 2021, and the close date is Jul 29, 2021. The issue may list on Aug 6, 2021.

Glenmark Life Sciences IPO Lot Size

The Glenmark Life Sciences IPO market lot size is 20 shares. A retail-individual investor can apply for up to 13 lots (260 shares or ₹187,200).

Application	Lots	Shares	Amount (Cut-off)
Minimum	1	20	₹14,400
Maximum	13	260	₹187,200

IPO how to invest in share market

Mirae Asset Nifty Financial Services ETF

About Nifty Financial Services Index

The Nifty Financial Services Index is designed to reflect the behavior and performance of large companies in financial services sector. The Nifty Financial Services Index comprises of 20 stocks that are listed on the National Stock Exchange (NSE)

Eligibility Criteria for Selection of Constituent Stocks:

• Company should belong to Financial Services sector and form part of NIFTY 500 Index at the time of review.
• The company should have a listing history of 6 months
• Final selection of 20 companies shall be done based on the free float market capitalization after considering the adequate representation of each segment.
• Weightage of each stock in the index is calculated based on its free-float market capitalization
• No single stock shall be more than 33% of the total and weightage of top 3 stocks cumulatively shall not be more than 62% of the total at the time of rebalancing.
• Index is re-balanced on semi-annual basis in March and September

 

Nifty Financial Services Index Portfolio

CompanyName	Weight
HDFCBank	24.40%
HousingDevelopmentFinance Corporation	16.70%
ICICIBank	16.30%
KotakMahindraBank	9.30%
AxisBank	7.20%
StateBankof India	6.00%
BajajFinance	6.00%
BajajFinserv	2.70%
HDFCLifeInsurance	2.10%
SBILifeInsurance	1.70%
ICICI LombardGeneralInsurance	1.30%
PiramalEnterprises	1.00%
ShriramTransportFinanceCo.	1.00%
ICICIPrudentialLifeInsurance	0.90%
Cholamandalam InvestmentandFinance	0.80%
HDFCAssetManagement	0.60%
MuthootFinance	0.60%
PowerFinanceCorporation	0.60%
REC	0.50%
Mahindra &MahindraFinancialServices	0.30%

 

 

 

Why invest in Mirae Asset Nifty Financial Services ETF ?

• Opportunity to participate in the sector which is essential for the overall growth of the economy.
• Financial Services encompasses not only banks but also other segments such as NBFC, Insurance, Capital Market etc. which are currently under-penetrated among masses.
• Nifty Financial Services Index has exhibited better return to risk profile along with lower drawdown vis-à-vis Nifty Bank Index.
• Overall actively managed BFSI funds are finding difficult to outperform Nifty Financial services Index across longer investment horizon.
• Relatively low cost option to participate in Financial Services Sector

NFO Details for Mirae Asset Nifty Financial Services ETF

• NFO Period : 22nd July 2021 – 29th July 2021
• Allotment Date : 30th July 2021
• Scheme re-open: 03rd August 2021
• Benchmark Index: Nifty Financial Services Total Return Index (TRI)
• Allotment Price: Offer for Sale of Units at 1/1000th value of the Nifty Financial Services Index on the date of allotment
• Listing: NSE & BSE (Maximum within 5 business days from the date of allotment)

to open dmat account with Angel broking use below link  https://tinyurl.com/k79bdf4z or write in comments

NFO, investment in etf  how to select a good etf mutual fund IPO

 

Tata Business Cycle Fund, NFO

 

Business Cycles: The economy goes through a series of stages as it expands and contracts, characterized by downward or upward fluctuations of GDP.

Periods of growth result in business activity rising, where businesses innovate, produce new products, create jobs and invest in further growth. At the peak of the expansion phase, businesses are using their full capacity, and soon continued innovation and investments have lower impact.

Periods of slowdown give businesses the opportunity to reorganize their operations and rebuild for future growth.

Businesses cut down on products and capacity and follow a more focused approach in their day to day functioning. At the trough of the slowdown phase, these renewed business models give rise to increased capacity and innovation.

Business Cycles Investing:

The returns investors achieve on their investments are driven in large part by changes in the business cycle. Each phase in the business cycle presents unique investment opportunities. So, incorporating business cycles theme into investments helps make the most of the current economic environment.

During a phase of recovery and expansion, Investments that are more sensitive to faster economic growth and business activity are likely outperform. There are generally referred to as cyclical stocks. These include:

• Stocks of midsize and small companies, as well as emerging market equities
• Younger, growth-oriented firms and industries

During a phase of slowdown and recession, Defensive investments and those that are sensitive to falling interest rates

have greater potential to outperform. There are generally referred to as defensive stocks. These include

• Stocks of larger and stable companies
• Businesses that experience steady consumer demand even during economic slowdowns

Investment Objective: To generate long-term capital appreciation by investing with focus on riding business cycles through allocation between sectors and stocks at different stages

of business cycles. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The scheme does not assure or guarantee any returns.

NFO Date NFO Opens: 16th July 2021 • NFO Closes: 30th July 2021

Min. Investment Amount: Minimum subscription amount: Rs 5,000/- and in multiple of Re.1/- thereafter Additional Purchase: Rs.1000/-& in multiples of Re.1/-threafter.

Load Structure: Entry Load: N.A.

Exit Load: Redemption/Switch-out/SWP/STP on or before expiry of 365 days from

the date of allotment: If the withdrawal amount or switched out amount is not

more than 12% of the original cost of investment-NIL

Redemption/Switch-out/SWP/STP on or before expiry of 365 days from the date of

allotment: If the withdrawal amount or switched out amount is more than 12% of

the original cost of investment-1% of applicable NAV

Redemption/Switch-out/SWP/STP after expiry of 365 days from the date of

allotment-NIL

This product is suitable for investors who are seeking*:

• Long Term Capital Appreciation.

• An equity scheme that invests predominantly in Indian markets with focus on riding business

cycles through dynamic allocation between various sectors and stocks at different stages of

business cycles.

To open dmat and trading account in Angel broking, use below link 

https://tinyurl.com/k79bdf4z

NFO, investment in etf  how to select a good etf mutual fund IPO

 

TRUSTMF Short Term Fund, NFO

 

TRUST Asset Management Company or AMC is a part of the renowned TRUST Group

known for its Thought Leadership and Financial Innovation particularly in the Fixed

Income space

TRUST AMC is committed to creating Differentiated, Innovative and Relevant

investment solutions.

This product is suitable for investors who are seeking*

• Income over short term

• Investment in debt money market instruments with portfolio

    Macaulay Duration between 1 3 years

·        PORTFOLIO RETURN SENSITIVITY –ROLL DOWN EFFECT

·        Illustration of Benefit from Roll down

• Steepness in the curve provides attractive opportunities for roll down benefits
• There is capital gain even if rates go up moderately
• Assumed Duration: 2 years*
• Assumed Portfolio Yield: 5.25%*
• Holding Period: 1 year
• Spread of 2 year over 1 year portfolio: 46 bps (based on 5 year average)
• Capital Gain due to roll down benefit: 0.44%

Interest rate Movement	(+) 50 bps	(+) 25 bps	Unchanged	(-)25 bps	(-)50 bps
PortfolioYield	5.25%	5.25%	5.25%	5.25%	5.25%
Capital Gain/loss dueto change in yield	(0.48%)	(0.24%)	0.00%	0.24%	0.48%
Capital Gain due to roll down	0.44%	0.44%	0.44%	0.44%	0.44%
Net Return	5.21%	5.45%	5.69%	5.93%	6.17%

 KEY TAKEAWAYS

• Focus on top quality investible universe of filtered AAA issuers
• Methodology of Portfolio Creation and Management
• Strategic Knowledge Partnership with CRISIL
• Consistent risk adjusted nominal returns in back testing of Model Portfolio calculated by CRISIL.
• Steep curves may provide an opportunity to generate capital gains due to roll down effect
• Current curve far steeper than historical averages

  

Particulars	Details
Product Category	Short DurationFund
Fund Manager	Anand Nevatia
Benchmark	CRISIL Short Term Bond Fund Index
Investment Objective	Theschemewillendeavortogeneratestablereturnsforinvestorswithashortterminvestmenthorizonbyinvestingindebtandmoneymarketinstruments. However,therecanbenoassurancethattheinvestmentobjectiveoftheschemewillbeachieved.
Exit Load	Nil
Custodian & Fund Accountant	HDFC Bank
Registrar & Transfer Agent	KFin Technologies Pvt Ltd
Macaulay Duration#	1 to 3years

 

To open dmat and trading account in Angel broking, use below link 

https://tinyurl.com/k79bdf4z

Tatva Chintan Pharma Chem Limited (Tatva Chintan)

 

Incorporated in 1996,

Tatva Chintan Pharma Chem Limited (Tatva Chintan) is a leading manufacturer of Structure Directing Agents (SDAs) and Phase Transfer Catalyst (PTCs) that have various applications in green chemistry. The company also manufactures Electrolyte Salts for super capacitor batteries (SCB) and Pharmaceutical & Agrochemical intermediates and other specialty chemicals (PASC). Its Product have application industries like automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavor and fragrances industries. As of FY21, they offered 47 products under their SDA, 48 products under the PTC, 6 products under the Electrolyte Salts for (SCB) and 53 products under their PASC portfolios. 

Positives: (a) Leading manufacturer of structure directing agents and phase transfer catalysts, with consistent quality. (b) Global presence with a wide customer base across various industries having high entry barriers. (c) Diversified specialized product portfolio requiring strong technical know-how (d) Modern manufacturing facilities with a focus on ‘green’ chemistry processes. (e) Strong R&D capabilities. 

Investment concerns: (a) Outbreak of the COVID-19 could have a significant effect on operations, and could negatively impact the business, revenues & financial condition (b) Unplanned slowdowns or shutdowns in manufacturing operations could have an adverse effect on business (c) Company is subject to quality requirements and strict technical specifications and audits by institutional customers. (d) Increase in the cost of raw materials. 

Outlook & Valuation: Tatva Chintan’s is the largest player in India for PTCs and the only manufacturer in India of SDAs for zeolites which have importance due to preference for green technologies. The company has shown good revenue and earnings growth and has healthy balance sheet with solid return ratios. It is raising funds for Capex and R&D requirements as they believe that there is strong growth opportunity available. Given the client additions, wide portfolio, its capabilities, and favorable outlook for the industry, we believe that Tatva Chintan can maintain healthy growth rates which justifies the ~46x FY21 EPS commanded by the company. Hence, we recommend “SUBSCRIBE” to the issue.

To open dmat and trading account in Angel broking, use below link 

https://tinyurl.com/k79bdf4z

NFO, investment in etf  how to select a good etf mutual fund IPO

 

ICICI PRUDENTIAL FLEXICAP FUND

To open free DMAT and Trading account with Angel Broking, use below link

https://tinyurl.com/k79bdf4z

ICICI PRUDENTIAL FLEXICAP FUND
(An open ended dynamic equity scheme investing across large cap, mid cap & small cap
stocks)
This scheme is suitable for investors who are seeking*:
*Long term wealth creation
*An open ended dynamic equity scheme investing
across large cap, mid cap and small cap stocks
New Fund Offer opens: June 28, 2021
New Fund Offer closes: July 12, 2021
Offer of Units of Rs. 10 each during the New Fund Offer period and continuous offer of Units at NAV based prices.
Face Value of units of the Scheme is Rs. 10/- per unit.

To open dmat and trading account in Angel broking, use below link 

https://tinyurl.com/k79bdf4z

NFO, investment in etf  how to select a good etf mutual fund IPO